Oct, 24 2020 Gilead Lifesciences Inc.'s Veklury (Remdesivir) has become the first treatment for COVID-19 to receive the U.S. Food and Drug Administration approval. The drug is approved for use in adult and pediatric patients 12 years of age and older…
July 6, 2020 Gilead Sciences has announced that the European Commission has granted conditional marketing authorization for Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing authorization was granted in the interest of public…
Recent Post
- Loan Licensing in Pharmaceutical Manufacturing: Key Principles, Guidelines, and Regulatory Framework
- Safe Handling of Narcotic and Psychotropic Drugs in a Wholesale Warehouse: A Complete Guide
- Understanding the Requirements for a Validation Master Plan (VMP) as per Regulatory Agencies: USFDA, EU GMP, MHRA, and PIC/S
- Complete Procedure to Meet CDSCO License Mandate of Class C & D Non-Notified Medical Devices
- Complete list of approved FDC